Journal
CNS DRUGS
Volume 26, Issue 3, Pages 189-204Publisher
ADIS INT LTD
DOI: 10.2165/11599770-000000000-00000
Keywords
-
Categories
Funding
- Department of Veterans Affairs
- National Institute of Mental Health [5R01MH81870, 1K23MH094707-01]
- NARSAD
- Mount Sinai Clinical and Translational Sciences Award [UL1RR029887]
- Evotec
- GlaxoSmithKline
- NIMH
- Novartis Pharmaceuticals
- PPD, Inc.
- Johnson Johnson
- Roche Pharmaceuticals
- Mount Sinai School of Medicine
- AstraZeneca
- Cephalon, Inc.
- Sanofi
Ask authors/readers for more resources
Currently available drugs for unipolar major depressive disorder (MDD), which target monoaminergic systems, have a delayed onset of action and significant limitations in efficacy. Antidepressants with primary pharmacological targets outside the monoamine system may offer the potential for more rapid activity with improved therapeutic benefit. The glutamate system has been scrutinized as a target for antidepressant drug discovery. The purpose of this article is to review emerging literature on the potential rapidonset antidepressant properties of the glutamate NMDA receptor antagonist ketamine, an established anaesthetic agent. The pharmacology of ketamine and its enantiomer S-ketamine is reviewed, followed by examples of its clinical application in chronic, refractory pain conditions, which are commonly co-morbid with depression. The first generation of studies in patients with treatment-resistant depression (TRD) reported the safety and acute efficacy of a single subanaesthetic dose (0.5 mg/kg) of intravenous ketamine. A second generation of ketamine studies is focused on testing alternate routes of drug delivery, identifying methods to prevent relapse following resolution of depressive symptoms and understanding the neural basis for the putative antidepressant actions of ketamine. In addition to traditional depression rating endpoints, ongoing research is examining the impact of ketamine on neuro-cognition. Although the first clinical report in MDD was published in 2000, there is a paucity of adequately controlled double-blind trials, and limited clinical experience outside of research settings. Given the potential risks of ketamine, safety considerations will ultimately determine whether this old drug is successfully repositioned as a new therapy for TRD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available